Silicone Effect on Corneal Endothelium and Corneal Biomechanics Using Corvis ST

March 2, 2025 updated by: Mohamed Yasser Sayed Saif, Beni-Suef University

Brief Summary

The goal of this observational study is to investigate the effects of silicone oil tamponade on corneal endothelial cell density (ECD), morphology, and biomechanics in patients undergoing vitrectomy for retinal detachment (20 patients, 20 eyes). The main questions it aims to answer are:

How does silicone oil tamponade affect corneal ECD, morphology, and biomechanics over 6 months postoperatively?

Are these changes associated with variations in best-corrected visual acuity (BCVA) or intraocular pressure (IOP)?

Comparison group: Researchers will compare preoperative measurements to 1-, 3-, and 6-month postoperative assessments to evaluate changes in endothelial parameters and corneal biomechanics.

Participants will:

Undergo preoperative and postoperative assessments (at 1, 3, and 6 months) using specular microscopy (to measure ECD, coefficient of variation, hexagonality) and Corvis ST (to evaluate biomechanical properties: Stress-Strain Index and deformation amplitude).

Have BCVA and IOP measured at each follow-up visit to track clinical outcomes.

Study Overview

Detailed Description

This prospective observational study evaluates the impact of silicone oil tamponade on corneal endothelial integrity and biomechanical properties in patients undergoing vitrectomy for retinal detachment. Below is an expanded description of the study protocol, emphasizing methodological rigor and technical specifics.

Study Design Type: Single-center, prospective, longitudinal observational study. Primary Objective: To quantify postoperative changes in corneal endothelial cell density (ECD), morphology, and biomechanical stability over a 6-month period following silicone oil tamponade.

Secondary Objectives:

Correlate corneal changes with clinical outcomes (BCVA, IOP).

Identify risk factors for endothelial cell loss or biomechanical weakening.

Rationale for Time Points: Assessments at 1, 3, and 6 months were selected to capture early postoperative stress responses (1 month), intermediate healing (3 months), and longer-term stabilization (6 months), aligning with standard vitrectomy follow-up protocols.

Participant Enrollment Recruitment: Consecutive patients scheduled for vitrectomy with silicone oil tamponade at a tertiary eye care center.

Informed Consent Process: Participants received detailed verbal and written explanations of study procedures, risks, and benefits prior to enrollment.

Data Collection Procedures Clinical and Imaging Assessments

Best-Corrected Visual Acuity (BCVA):

Measured using Snellen charts under standardized lighting conditions.

Converted to logMAR for statistical analysis.

Intraocular Pressure (IOP):

Assessed via Goldmann applanation tonometry (calibrated weekly), with three consecutive readings averaged.

Corneal Endothelial Analysis:

Specular Microscopy (Konan Noncon Robo NSP-9900):

Parameters:

Endothelial Cell Density (ECD): Cells/mm².

Coefficient of Variation (CV): Reflects cell size variability (polymegathism).

Hexagonality: Percentage of hexagonal cells (pleomorphism).

Protocol: Central corneal measurements taken in triplicate, with the median value recorded.

Corneal Biomechanical Evaluation:

Corvis ST (Oculus Optikgeräte GmbH):

Parameters:

Stress-Strain Index (SSI): Quantifies corneal stiffness.

Deformation Amplitude (DA): Maximum corneal displacement during air-puff applanation.

Protocol: Three valid scans per eye, performed under mesopic conditions.

Follow-Up Protocol Baseline: Preoperative assessment within 1 week of surgery.

Postoperative: Follow-up visits at 1, 3, and 6 months (±7 days), including:

BCVA and IOP measurement.

Specular microscopy and Corvis ST imaging.

Documentation of complications (e.g., corneal edema, elevated IOP).

Quality Assurance Measures

Equipment Calibration:

Specular microscopy and Corvis ST devices underwent daily calibration checks and quarterly manufacturer servicing.

Standardized Protocols:

All measurements performed by a single trained ophthalmologist to minimize inter-observer variability.

Consistent time-of-day scheduling for IOP assessments (9 AM-11 AM) to control diurnal fluctuations.

Blinded Analysis:

Endothelial and biomechanical data were analyzed by masked investigators unaware of clinical outcomes or time points.

Data Management and Statistical Analysis

Data Storage:

Clinical and imaging data stored in a HIPAA-compliant REDCap database with role-based access.

Regular backups to encrypted cloud storage.

Statistical Methods:

Primary Analysis: Linear mixed-effects models to evaluate longitudinal changes in ECD, SSI, and DA.

Secondary Analysis: Pearson/Spearman correlations between endothelial parameters, biomechanics, and BCVA/IOP.

Missing Data: Multiple imputation used for sporadic missing follow-up data (<10% attrition anticipated).

Software: Analyses performed using R (v4.3.1) and SPSS (v28.0).

Ethical and Safety Considerations

Adverse Event Management:

Complications (e.g., corneal decompensation, IOP spikes) were managed per institutional guidelines and reported to the IRB.

Protocol Compliance:

Internal audits conducted quarterly to ensure adherence to GCP and study protocols.

Technical Rationale Silicone Oil Tamponade: While effective for retinal reattachment, silicone oil may mechanically stress the corneal endothelium or alter aqueous humor dynamics, potentially accelerating cell loss.

Biomechanical Relevance: Corneal stiffness (SSI) and deformability (DA) are critical for refractive stability and surgical planning (e.g., cataract surgery post-vitrectomy).

Clinical Implications

This study aims to provide evidence-based recommendations for:

Timing of silicone oil removal to mitigate corneal damage.

Enhanced monitoring strategies for high-risk patients.

Personalized interventions to preserve endothelial health.

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Fayoum, Egypt
        • Fayoum university hospital
      • Giza, Egypt
        • Misr University for Science and Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing vitrectomy with silicone oil tamponade for the treatment of rhegmatogenous retinal detachment (RRD).

Description

Inclusion Criteria:

  • Patients undergoing vitrectomy.
  • Clear cornea.
  • Central corneal thickness (CCT) ≥ 500 µm.
  • Age between 20 and 50 years.

Exclusion Criteria:

  • History of intraocular surgery.
  • Ocular pathologies, such as corneal scarring or dystrophy.
  • Advanced keratoconus.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group (A)
Vitrectomy with 1000 cSt silicone oil.

Corvis ST is used to assess corneal biomechanical changes following vitrectomy with silicone oil tamponade, specifically:

Corneal stiffness and elasticity using the Stress-Strain Index (SSI) Corneal deformation response via Deformation Amplitude (DA)

Other Names:
  • Corneal Biomechanics

The study evaluates the impact of silicone oil tamponade on corneal endothelial cell density (ECD) in patients undergoing vitrectomy for retinal detachment. The intervention involves:

Preoperative and Postoperative Assessments at 1, 3, and 6 months to monitor changes in ECD.

Specular Microscopy to measure ECD (cells/mm²), coefficient of variation (CV) in cell size, and hexagonality (% of hexagonal cells).

group (B)
Phaco vitrectomy with 1000 cSt silicone oil.

Corvis ST is used to assess corneal biomechanical changes following vitrectomy with silicone oil tamponade, specifically:

Corneal stiffness and elasticity using the Stress-Strain Index (SSI) Corneal deformation response via Deformation Amplitude (DA)

Other Names:
  • Corneal Biomechanics

The study evaluates the impact of silicone oil tamponade on corneal endothelial cell density (ECD) in patients undergoing vitrectomy for retinal detachment. The intervention involves:

Preoperative and Postoperative Assessments at 1, 3, and 6 months to monitor changes in ECD.

Specular Microscopy to measure ECD (cells/mm²), coefficient of variation (CV) in cell size, and hexagonality (% of hexagonal cells).

group (C)
Vitrectomy with 5000 cSt silicone oil.

Corvis ST is used to assess corneal biomechanical changes following vitrectomy with silicone oil tamponade, specifically:

Corneal stiffness and elasticity using the Stress-Strain Index (SSI) Corneal deformation response via Deformation Amplitude (DA)

Other Names:
  • Corneal Biomechanics

The study evaluates the impact of silicone oil tamponade on corneal endothelial cell density (ECD) in patients undergoing vitrectomy for retinal detachment. The intervention involves:

Preoperative and Postoperative Assessments at 1, 3, and 6 months to monitor changes in ECD.

Specular Microscopy to measure ECD (cells/mm²), coefficient of variation (CV) in cell size, and hexagonality (% of hexagonal cells).

group (D)
Phaco vitrectomy with 5000 cSt silicone oil.

Corvis ST is used to assess corneal biomechanical changes following vitrectomy with silicone oil tamponade, specifically:

Corneal stiffness and elasticity using the Stress-Strain Index (SSI) Corneal deformation response via Deformation Amplitude (DA)

Other Names:
  • Corneal Biomechanics

The study evaluates the impact of silicone oil tamponade on corneal endothelial cell density (ECD) in patients undergoing vitrectomy for retinal detachment. The intervention involves:

Preoperative and Postoperative Assessments at 1, 3, and 6 months to monitor changes in ECD.

Specular Microscopy to measure ECD (cells/mm²), coefficient of variation (CV) in cell size, and hexagonality (% of hexagonal cells).

group (E)
Control group (other eyes).

Corvis ST is used to assess corneal biomechanical changes following vitrectomy with silicone oil tamponade, specifically:

Corneal stiffness and elasticity using the Stress-Strain Index (SSI) Corneal deformation response via Deformation Amplitude (DA)

Other Names:
  • Corneal Biomechanics

The study evaluates the impact of silicone oil tamponade on corneal endothelial cell density (ECD) in patients undergoing vitrectomy for retinal detachment. The intervention involves:

Preoperative and Postoperative Assessments at 1, 3, and 6 months to monitor changes in ECD.

Specular Microscopy to measure ECD (cells/mm²), coefficient of variation (CV) in cell size, and hexagonality (% of hexagonal cells).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Corneal Endothelial Cell Density (ECD)
Time Frame: Baseline (preoperative), 1 month, 3 months, and 6 months postoperatively.
Measurement: Cells/mm², assessed via specular microscopy (Konan Noncon Robo NSP-9900).
Baseline (preoperative), 1 month, 3 months, and 6 months postoperatively.
Morphological Changes in Corneal Endothelium
Time Frame: Baseline, 1, 3, and 6 months.

Parameters:

Coefficient of Variation (CV): Reflects cell size variability (polymegathism).

Hexagonality: Percentage of hexagonal cells (pleomorphism).

Measurement: Specular microscopy.

CV and hexagonality are vital for evaluating corneal endothelial health. Optimal outcomes are associated with low CV (<30%) and high hexagonality (>60%), while deviations signal pathology or risk. Specular microscopy remains the gold standard for non-invasive assessment.

Baseline, 1, 3, and 6 months.
Corneal Biomechanical Properties
Time Frame: Baseline, 1, 3, and 6 months.

Parameters:

Stress-Strain Index (SSI): Quantifies corneal stiffness.

Deformation Amplitude (DA): Maximum corneal displacement during air-puff applanation.

Measurement: Corvis ST (Oculus Optikgeräte GmbH).

Normal Ranges:

SSI: Typically ranges between ~50-100 (unitless), though values vary by population and device software.

DA: Normal corneas average ~1.0-1.2 mm, while keratoconic corneas often exceed 1.3 mm.

Baseline, 1, 3, and 6 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Best-Corrected Visual Acuity (BCVA)
Time Frame: Baseline, 1, 3, and 6 months.
Snellen charts converted to logMAR for analysis.
Baseline, 1, 3, and 6 months.
Intraocular Pressure (IOP)
Time Frame: Baseline, 1, 3, and 6 months.
Goldmann applanation tonometry (average of three readings).
Baseline, 1, 3, and 6 months.
Correlation Between Corneal Changes and Clinical Outcomes
Time Frame: Baseline, 1, 3, and 6 months.
Associations between ECD, biomechanical parameters (SSI/DA), and BCVA/IOP using regression models.
Baseline, 1, 3, and 6 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2022

Primary Completion (Actual)

October 1, 2024

Study Completion (Actual)

December 31, 2024

Study Registration Dates

First Submitted

February 21, 2025

First Submitted That Met QC Criteria

March 2, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 2, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Corneal Biomechanics

Clinical Trials on Corvis ST

Subscribe